MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329636 | Name: Pasireotide diaspartate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Chemical Structure

Pasireotide diaspartate
Pasireotide diaspartate
CAS#820232-50-6 (diaspartate)

Theoretical Analysis

MedKoo Cat#: 329636

Name: Pasireotide diaspartate

CAS#: 820232-50-6 (diaspartate)

Chemical Formula: C66H80N12O17

Exact Mass: 0.0000

Molecular Weight: 1313.43

Elemental Analysis: C, 60.36; H, 6.14; N, 12.80; O, 20.71

Price and Availability

Size Price Availability Quantity
1mg USD 250.00
5mg USD 725.00
10mg USD 1,350.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
396091-73-9 (free base) 396091-76-2 (acetate) 396091-79-5 (pamoate) 820232-50-6 (diaspartate)
Synonym
Pasireotide diaspartate, SOM 230; SOM-230; SOM230; trade name: Signifor; Signifor LAR.
IUPAC/Chemical Name
(3S,6R,9S,12S,15S,19R,20aS)-6-((1H-indol-3-yl)methyl)-9-(4-aminobutyl)-15-benzyl-12-(4-(benzyloxy)benzyl)-1,4,7,10,13,16-hexaoxo-3-phenylicosahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecin-19-yl (2-aminoethyl)carbamate bis(L-aspartate)
InChi Key
NEEFMPSSNFRRNC-HQUONIRXSA-N
InChi Code
InChI=1S/C58H66N10O9.2C4H7NO4/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45;2*5-2(4(8)9)1-3(6)7/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72);2*2H,1,5H2,(H,6,7)(H,8,9)/t43-,46+,47+,48-,49+,50+,51+;2*2-/m100/s1
SMILES Code
N[C@@H](CC(O)=O)C(O)=O.N[C@@H](CC(O)=O)C(O)=O.O=C(O[C@@H](C1)C[C@](C(N[C@@H](C2=CC=CC=C2)C(N[C@H](CC3=CNC4=C3C=CC=C4)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CC=C(OCC6=CC=CC=C6)C=C5)C(N[C@H]7CC8=CC=CC=C8)=O)=O)=O)=O)=O)([H])N1C7=O)NCCN
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,313.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dabbous Z, Rohani Z, Abdalrubb AK, Alkailani Y, Pivonello R, Elhadd T. Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. JCEM Case Rep. 2024 Aug 9;2(8):luae142. doi: 10.1210/jcemcr/luae142. PMID: 39129819; PMCID: PMC11311708. 2: Doknic M, Stojanovic M, Miljic D, Milicevic M. Medical treatment of acromegaly - When the tumor size matters: A narrative review. Growth Horm IGF Res. 2024 Aug 2;78:101608. doi: 10.1016/j.ghir.2024.101608. Epub ahead of print. PMID: 39116789. 3: Zhang B, Xue L, Wu ZB. Structure and Function of Somatostatin and its Receptors in Endocrinology. Endocr Rev. 2024 Aug 8:bnae022. doi: 10.1210/endrev/bnae022. Epub ahead of print. PMID: 39116368. 4: Mondin A, Ceccato F, Scaroni C, Barbot M. Long-term Remission in Functioning Pituitary Adenomas after Medical Therapy Withdrawal: A Chance for Cushing's Disease. Endocr Metab Immune Disord Drug Targets. 2024 Jul 30. doi: 10.2174/0118715303328077240719055819. Epub ahead of print. PMID: 39082175. 5: De Fano M, Falorni A, Malara M, Porcellati F, Fanelli CG. Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review. Diabetes Metab Syndr Obes. 2024 Jul 23;17:2761-2774. doi: 10.2147/DMSO.S466328. PMID: 39072348; PMCID: PMC11283249. 6: Doello K, Chico MA, Quiñonero F, Ortiz R, Prados J, Mesas C, Melguizo C. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide. Medicina (Kaunas). 2024 Jun 25;60(7):1039. doi: 10.3390/medicina60071039. PMID: 39064468; PMCID: PMC11279282. 7: Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E, Rodríguez Berrocal V, Guerrero-Pérez F, Vicente A, Carlos Percovich Hualpa J, García-Centeno R, González-Fernández L, Dolores Ollero García M, Irigaray Echarri A, Dolores Moure Rodríguez M, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Benítez Valderrama P, Tenorio-Jiménez C, Abellán Galiana P, Venegas E, González-Molero I, Iglesias P, Blanco-Carrera C, Vidal-Ostos De Lara F, de Miguel Novoa P, López Mezquita E, Alexandra Hanzu F, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Q, Gracia Gimeno P, María Recio-Córdova J, Dolores Avilés-Pérez M, Asensio-Wandosell D, Sampedro- Núñez M, Cámara R, Paja Fano M, Ruz-Caracuel I, Fajardo C, Marazuela M, Puig- Domingo M. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer. 2024 Jul 25;31(9):x240043. doi: 10.1530/ERC-24-0043e. PMID: 39059428. 8: Costanza F, Chiloiro S, Giampietro A, Angelini F, Infante A, Pontecorvi A, De Marinis L, Bianchi A. The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First- generation SSAs and Treated with Pegvisomant or Pasireotide LAR. Endocr Metab Immune Disord Drug Targets. 2024 Jul 5. doi: 10.2174/0118715303322301240610111946. Epub ahead of print. PMID: 38982703. 9: Chauhan SSB, Vierra B, Park JO, Pillarisetty VG, Davidson GH, Sham JG. Prophylactic somatostatin analogs for postoperative pancreatic fistulas: a cross-sectional survey of AHPBA surgeons. HPB (Oxford). 2024 Jun 15:S1365-182X(24)01768-4. doi: 10.1016/j.hpb.2024.06.002. Epub ahead of print. PMID: 38971667. 10: Telehuz D, Plesa O, Bouilloud F, Wucher H, De Lonlay P, Bérat CM, Saint- Martin C, Dupuy O, Arnoux JB. Case report: Exceptional transmission of congenital hyperinsulinism from a focal CHI mother to her diffuse CHI dichorionic diamniotic twins. Front Endocrinol (Lausanne). 2024 Jun 17;15:1408003. doi: 10.3389/fendo.2024.1408003. PMID: 38952388; PMCID: PMC11215135. 11: Li YG, Meng XY, Yang X, Ling SL, Shi P, Tian CL, Yang F. Structural insights into somatostatin receptor 5 bound with cyclic peptides. Acta Pharmacol Sin. 2024 Jun 26. doi: 10.1038/s41401-024-01314-8. Epub ahead of print. PMID: 38926478. 12: Arlien-Søborg MC, Dal J, Heck A, Stochholm K, Husted E, Feltoft CL, Rasmussen ÅK, Feldt-Rasmussen U, Andreassen M, Klose MC, Nielsen TL, Andersen MS, Christensen LL, Krogh J, Jarlov A, Bollerslev J, Nermoen I, Oksnes M, Dahlqvist P, Olsson T, Berinder K, Hoybye C, Petersson M, Akerman AK, Wahlberg J, Ekman B, Engstrom BE, Johannsson G, Ragnarsson O, Olsson D, Sigurjónsdóttir HÁ, Fougner SL, Matikainen N, Vehkavaara S, Metso S, Jaatinen P, Hämäläinen P, Rintamäki R, Yliaska I, Immonen H, Mäkimattila S, Cederberg-Tamminen H, Viukari M, Nevalainen P, Nuutila P, Schalin-Jäntti C, Burman P, Jørgensen JOL. Acromegaly management in the Nordic countries: A Delphi consensus survey. Clin Endocrinol (Oxf). 2024 Sep;101(3):263-273. doi: 10.1111/cen.15095. Epub 2024 Jun 12. PMID: 38865284. 13: Hashemi-Madani N, Cheraghi S, Emami Z, Mehrjardi AZ, Kaynama MR, Khamseh ME. Targeted analysis of Ubiquitin-Specific Peptidase (USP8) in a population of Iranian people with Cushing's disease and a systematic review of the literature. BMC Endocr Disord. 2024 Jun 11;24(1):86. doi: 10.1186/s12902-024-01619-z. PMID: 38862897; PMCID: PMC11165846. 14: Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF. Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary. 2024 Aug;27(4):381-388. doi: 10.1007/s11102-024-01397-w. Epub 2024 Jun 4. PMID: 38833044; PMCID: PMC11289172. 15: Chiloiro S, Appetecchia M, Bianchi A, Costa D, De Acetis C, Gargiulo P, Giampietro A, Isidori AM, Jaffrain-Rea ML, Passeri M, Pigliaru F, Poggi M, De Marinis L. Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences. Drugs Context. 2024 May 20;13:2024-1-2. doi: 10.7573/dic.2024-1-2. PMID: 38817802; PMCID: PMC11139163. 16: Grottoli S, Maffei P, Tresoldi AS, Granato S, Benedan L, Mariani P, Giustina A. Insights from an Italian Delphi panel: exploring resistance to first- generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. J Endocrinol Invest. 2024 May 29. doi: 10.1007/s40618-024-02386-3. Epub ahead of print. PMID: 38809458. 17: Hayes AG, Penny MJ, Aivazian K, Greenfield JR. Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly. JCEM Case Rep. 2024 May 20;2(5):luae071. doi: 10.1210/jcemcr/luae071. PMID: 38770226; PMCID: PMC11104526. 18: Saha S, Sharma A, Bhowmik D, Kumar D. Investigation into in silico and in vitro approaches for inhibitors targeting MCM10 in Leishmania donovani: a comprehensive study. Mol Divers. 2024 May 9. doi: 10.1007/s11030-024-10876-y. Epub ahead of print. PMID: 38722455. 19: Chiloiro S, Giampietro A, Infante A, Mattogno PP, Lauretti L, Olivi A, De Marinis L, Pontecorvi A, Doglietto F, Bianchi A. Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience. Pituitary. 2024 Jun;27(3):303-309. doi: 10.1007/s11102-024-01398-9. Epub 2024 May 7. PMID: 38713317. 20: Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E, Rodríguez Berrocal V, Guerrero-Pérez F, Vicente A, Percovich Hualpa JC, García-Centeno R, González-Fernández L, Ollero García MD, Irigaray Echarri A, Moure Rodríguez MD, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Benítez Valderrama P, Tenorio-Jiménez C, Abellán Galiana P, Venegas E, González-Molero I, Iglesias P, Blanco-Carrera C, Vidal- Ostos De Lara F, de Miguel Novoa P, López Mezquita E, Hanzu FA, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Q, Gracia Gimeno P, Recio-Córdova JM, Avilés-Pérez MD, Asensio-Wandosell D, Sampedro-Núñez M, Cámara R, Paja Fano M, Ruz-Caracuel I, Fajardo C, Marazuela M, Puig-Domingo M. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer. 2024 May 27;31(7):e240043. doi: 10.1530/ERC-24-0043. PMID: 38713182.